3
Participants
Start Date
December 6, 2021
Primary Completion Date
August 26, 2022
Study Completion Date
August 26, 2022
KRT-232
Administered by mouth
Hospital General Universitario de Alicante, Alicante
Flinders Medical Centre, Bedford Park
Bacs Kiskun Megyei Korhaz, Kecskemét
Evangelische Lungenklinik Berlin, Berlin
CHA Bundang Medical Center, CHA University, Seongnam-si
Hopital Nord AP-HM, Marseille
Hospital Universitario 12 de Octubre, Alicante
Clinica Universidad Navarra - Madrid, Madrid
Hospital Universitario La Paz, Madrid
Chungbuk National University Hospital, Cheongju-si
Hospital Regional Universitario de Malaga - Hospital Civil, Málaga
Northwest Georgia Oncology Centers, Marietta
Clinica Universidad Navarra, Pamplona
EDOG - Institut Bergonie - PPDS, Bordeaux
Florida Cancer Specialists, West Palm Beach
Florida Cancer Specialists - 560 Jackson St, Suite 220, St. Petersburg
Florida Cancer Specialists - 3840 Broadway, Fort Myers
Lungenfachklinik Immenhausen, Immenhausen
SCRI Tennessee Oncology Nashville, Nashville
SCRI Tennessee Oncology Chattanooga, Chattanooga
CHU de Grenoble, Grenoble
Hospital Universitario Virgen Macarena, Seville
Mark H Zangmeister Center - 3100 Plaza Properties Boulevard, Columbus
University Hospitals Cleveland Medical Center, Cleveland
Hospital Universitari i Politecnic La Fe de Valencia, Valencia
Edog - Ico - Ppds, Angers
Centre Hospitalier de Mulhouse - Hopital Emile Muller, Mulhouse
Hôpital de La Croix Rousse, Pierre-Bénite
Hospices Civils de Lyon, Lyon
Hôpital Louis Pradel, Bron
Hematology Oncology Clinic, Baton Rouge
Klinik für Kardiologie, Angiologie und Pneumologie, Esslingen am Neckar
Hospital Universitario Vall d'Hebrón - PPDS, Barcelona
Lead Sponsor
Kartos Therapeutics, Inc.
INDUSTRY